Eli Lilly

Amgen, Lilly, Merck sue HHS to block price disclosures in DTC ads
Amgen, Lilly, Merck sue HHS to block price disclosures in DTC ads
BioCentury
HHS
DTC ads
television ads
Merck
Eli Lilly
Amgen
Flag link:
Lilly’s Taltz scrapes win against Humira in psoriatic arthritis
Lilly’s Taltz scrapes win against Humira in psoriatic arthritis
Pharmaforum
Eli Lilly
Taltz
AbbVie
Humira
psoriatic arthritis
Flag link:
House progressives challenge drugmakers to come back to Capitol Hill
House progressives challenge drugmakers to come back to Capitol Hill
Stat
Democrats
drug pricing
Pfizer
Merck
Eli Lilly
Gilead Sciences
Mylan
Mallinckrodt
Flag link:
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Fierce Pharma
Eli Lilly
Incyte
olumiant
safety data
Humira
rheumatoid arthritis
Flag link:
Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales
Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales
Fierce Pharma
Eli Lilly
Taltz
psoriasis
Flag link:
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
ADA
diabetes
Tradjenta
Flag link:
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Fierce Biotech
Eli Lilly
NASH
tirzepatide
clinial trials
ADA
type 2 diabetes
Flag link:
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Fierce Pharma
Eli Lilly
ADA
diabetes
heart attack
stroke
Trulicity
Novo Nordisk
semaglutide
Flag link:
Eli Lilly throws SCOTUS hail mary in Cialis patent infringement fight
Eli Lilly throws SCOTUS hail mary in Cialis patent infringement fight
Fierce Pharma
Eli Lilly
Cialis
patents
Patent Infringement
benign prostatic hyperplasia
Supreme Court
Flag link:
Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction
Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction
TheStreet.com
Eli Lilly
Emgality
cluster headaches
Flag link:
Lilly's scored its cluster headache nod for Emgality. Will it shake up the CGRP race?
Lilly's scored its cluster headache nod for Emgality. Will it shake up the CGRP race?
Fierce Pharma
Eli Lilly
Emgality
cluster headaches
Flag link:
Eli Lilly, BMS among 77 drugmakers targeted in Chinese financial probe
Eli Lilly, BMS among 77 drugmakers targeted in Chinese financial probe
Fierce Pharma
China
Sanofi
Eli Lilly
Bristol-Myers Squibb
Flag link:
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
Flag link:
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
BioCentury
Blueprint Medicines
BLU-667
ASCO 2019
Eli Lilly
RET-altered cancer
LOXO-292
Flag link:
A bruised Eli Lilly buys rights to Centrexion’s early-stage pain drug for $47.5M upfront
A bruised Eli Lilly buys rights to Centrexion’s early-stage pain drug for $47.5M upfront
Endpoints
Eli Lilly
non-opioid pain treatments
Centrexion
CNTX-0290
Flag link:
Eli Lilly’s Generic Insulin Hits Market at Half the Price of Branded Counterpart
Eli Lilly’s Generic Insulin Hits Market at Half the Price of Branded Counterpart
BioSpace
Eli Lilly
drug pricing
generics
insulin
diabetes
Lispro
KwikPens
Flag link:
Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease
Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease
Pharmaceutical Business Review
Eli Lilly
Crohn's Disease
mirikizumab
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Incyte
Novartis
Athersys
ResTORbio
Bellerophon Therapeutics
Eli Lilly
CymaBay
Bicycle Therapeutics
Peloton Therapeutics
Ideaya
IPOs
Flag link:
3 Top Diabetes Stocks to Watch in May
3 Top Diabetes Stocks to Watch in May
Motley Fool
diabetes
AstraZeneca
Eli Lilly
Medtronic
Flag link:
How can Teva's migraine drug face off Amgen and Lilly? Put neurologists first, DTC last, executive says
How can Teva's migraine drug face off Amgen and Lilly? Put neurologists first, DTC last, executive says
Fierce Pharma
Teva Pharmaceutical
migraines
Ajovy
Amgen
Eli Lilly
Emgality
Aimovig
neurologists
physicians
DTC advertising
Flag link:

Pages